Rev-erb regulation of cholesterologenesis

Biochemical Pharmacology

Volumn 131, Issue , 2017, Pages 68-77

  Sitaula, Sadichha ^a   Zhang, Jinsong ^a   Ruiz, Fernanda ^a   Burris, Thomas P ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cholesterol synthesis; Nuclear receptor; Rev erb; Statins

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HISTONE DEACETYLASE 3; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NUCLEAR RECEPTOR NR1D1; SR 9009; STEROL 14ALPHA DEMETHYLASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CHOLESTEROL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BINDING SITE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CHROMATIN IMMUNOPRECIPITATION; CIRCADIAN RHYTHM; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; GENE EXPRESSION; HEP-G2 CELL LINE; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SEQUENCE ANALYSIS; UPREGULATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; GENETICS; HEK293 CELL LINE; KNOCKOUT MOUSE; PHYSIOLOGY;

ANIMALS; CHOLESTEROL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT;

EID: 85014024105     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2017.02.006     Document Type: Article

References (38)

1. [1] Maxfield, F.R., Tabas, I., Role of cholesterol and lipid organization in disease. Nature 438 (2005), 612–621.
2. [2] Tint, G.S., Irons, M., Elias, E.R., Batta, A.K., Frieden, R., Chen, T.S., et al. Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. N. Engl. J. Med. 330:2 (1994), 107–113.
3. [3] Kritchevsky, D., Cholesterol and atherosclerosis. Am. J. Clin. Nutr. 10:19 (1962), 269–276.
4. [4] Gylling, H., Hallikainen, M., Kolehmainen, M., Toppinen, L., Pihlajamäki, J., Mykkänen, H., et al. Cholesterol synthesis prevails over absorption in metabolic syndrome. Transl. Res. 149:6 (2007), 310–316.
5. [5] Di Paolo, G., Kim, T.-W., Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat. Rev. Neurosci. 12 (2011), 284–296.
6. [6] Moschetta, A., Bookout, A.L., Mangelsdorf, D.J., Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat. Med. 10:12 (2004), 1352–1358.
7. [7] S.A. Murphy, C.P. Cannon, S.D. Wiviott, C.H. McCabe, E. Braunwald, Reduction in Recurrent Cardiovascular Events With Intensive Lipid-Lowering Statin Therapy Compared With Moderate Lipid-Lowering Statin Therapy After Acute Coronary Syndromes: From the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22) Trial, J. Am. Coll. Cardiol., 54(25), 2009, 2358–2362, Dec. 15AD.
8. [8] Ahn, C.H., Choi, S.H., New drugs for treating dyslipidemia: beyond statins. Diabetes Metab. J. 39:2 (2015), 87–94.
9. [9] Lazar, M.A., Hodin, R.A., Darling, D.S., Chin, W.W., A novel member of the thyroid/steroid hormone receptor family is encoded by the opposite strand of the rat c-erbA alpha transcriptional unit. Mol. Cell. Biol. 9:3 (1989), 1128–1136.
10. [10] Raghuram, S., Stayrook, K.R., Huang, P., Rogers, P.M., Nosie, A.K., McClure, D.B., et al. Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta. Nat. Struct. Mol. Biol. 14 (2007), 1207–1213.
11. [11] Yin, L., Wu, N., Curtin, J.C., Qatanani, M., Szwergold, N.R., Reid, R.A., et al. Rev-erbalpha, a heme sensor that coordinates metabolic and circadian pathways. Science 318 (2007), 1786–1789.
12. [12] Forman, B.M., Chen, J., Blumberg, B., Kliewer, S., Henshaw, R., Ong, E.S., et al. Cross-talk among ROR alpha 1 and the Rev-erb family of orphan nuclear receptors. Mol. Endocrinol. 8:9 (1994), 1253–1261.
13. [13] Adelmant, G., Bègue, A., Stéhelin, D., Laudet, V., A functional Rev-erb alpha responsive element located in the human Rev-erb alpha promoter mediates a repressing activity. Proc. Natl. Acad. Sci. U.S.A. 93:8 (1996), 3553–3558.
14. [14] Yin, L., Lazar, M., The orphan nuclear receptor Rev-erbalpha recruits the N-CoR/histone deacetylase 3 corepressor to regulate the circadian Bmal1 gene. Mol. Endocrinol. 19:6 (2005), 1452–1459.
15. [15] Cho, H., Zhao, X., Hatori, M., Yu, R.T., Barish, G.D., Lam, M.T., et al. Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-β. Nature 485 (2012), 123–127.
16. [16] Feng, D., Liu, T., Sun, Z., Bugge, A., Mullican, S.E., Alenghat, T., et al. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science 331:2011 (2011), 1315–1319.
17. [17] Bugge, A., Feng, D., Everett, L.J., Briggs, E.R., Mullican, S.E., Wang, F., et al. Rev-erbα and Rev-erbβ coordinately protect the circadian clock and normal metabolic function. Genes Dev. 26 (2012), 657–667.
18. [18] Delezie, J., Dumont, S., Dardente, H., Oudart, H., Grechez-Cassiau, A., Klosen, P., et al. The nuclear receptor REV-ERB is required for the daily balance of carbohydrate and lipid metabolism. FASEB J. 26 (2012), 3321–3335.
19. [19] Solt, L.A., Wang, Y., Banerjee, S., Hughes, T., Kojetin, D.J., Lundasen, T., et al. Regulation of circadian behavior and metabolism by synthetic REV-ERB agonists. Nature 485:7396 (2012), 62–68.
20. [20] Zhang, Y., Fang, B., Emmett, M.J., Damle, M., Sun, Z., Feng, D., et al. Discrete functions of nuclear receptor Rev-erbα couple metabolism to the clock. Science 348:6242 (2015), 1488–1492.
21. [21] Fang, B., Everett, L.J., Jager, J., Briggs, E., Armour, S.M., Feng, D., et al. Circadian enhancers coordinate multiple phases of rhythmic gene transcription in vivo. Cell 159:5 (2014), 1140–1152.
22. [22] Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38:4 (2010), 576–589.
23. [23] Chen, J., Xu, H., Aronow, B.J., Jegga, A.G., Improved human disease candidate gene prioritization using mouse phenotype. BMC Bioinformatics, 8, 2007, 392.
24. [24] Potteaux, S., Ait-Oufella, H., Mallat, Z., Mouse models of atherosclerosis. Drug Discov. Today Dis. Model. 4:4 (2007), 165–170.
25. [25] Ericsson, J., Jackson, S.M., Lee, B.C., Edwards, P.A., Sterol regulatory element binding protein binds to a cis element in the promoter of the farnesyl diphosphate synthase gene. Proc. Natl. Acad. Sci. U.S.A. 93 (1996), 945–950.
26. [26] Guan, G.M., Jiang, G.J., Koch, R.L., Shechter, I., Molecular-cloning and functional-analysis of the promoter of the human squalene synthase gene. J. Biol. Chem. 270 (1995), 21958–21965.
27. [27] Robinson, M.D., Oshlack, A., A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol., 11(3), 2010, R25.
28. [28] Robinson, M.D., McCarthy, D.J., Smyth, G.K., EdgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26:1 (2010), 139–140.
29. [29] Crumbley, C., Burris, T.P., Direct regulation of CLOCK expression by REV-ERB. PLoS One, 6(3), 2011, e17290.
30. [30] Zhang, Y., Fang, B., Damle, M., Guan, D., Li, Z., Kim, Y., et al. HNF6 and Rev-erb α integrate hepatic lipid metabolism by overlapping and distinct transcriptional mechanisms. Genes Dev. 30 (2016), 1636–1644.
31. [31] Horton, J.D., Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem. Soc. Trans. 30 (2002), 1091–1095.
32. [32] Tang, J.-J., Li, J.-G., Qi, W., Qiu, W.-W., Li, P.-S., Li, B.-L., et al. Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. Cell Metab. 13:1 (Jan. 2011), 44–56.
33. [33] Sato, R., Inoue, J., Kawabe, Y., Kodama, T., Takano, T., Maeda, M., Sterol-dependent transcriptional regulation of sterol regulatory element-binding protein-2. J. Biol. Chem. 271:43 (1996), 26461–26464.
34. [34] Kamisuki, S., Mao, Q., Abu-Elheiga, L., Gu, Z., Kugimiya, A., Kwon, Y., et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem. Biol. 16:8 (Aug. 2009), 882–892.
35. [35] Zhao, X., Xiaoli, Zong, H., Abdulla, A., Yang, E.S.T., Wang, Q., et al. Inhibition of SREBP transcriptional activity by a boron-containing compound improves lipid homeostasis in diet-induced obesity. Diabetes 63:7 (2014), 2464–2473.
36. [36] Ma, H., Zhong, W., Jiang, Y., Fontaine, C., Li, S., Fu, J., et al. Increased atherosclerotic lesions in LDL receptor deficient mice with hematopoietic nuclear receptor Rev-erbα knock-down. J. Am. Heart Assoc., 2, 2013, e000235.
37. [37] Sitaula, S., Billon, C., Kamenecka, T.M., Solt, L.A., Burris, T.P., Suppression of atherosclerosis by synthetic REV-ERB agonist. Biochem. Biophys. Res. Commun. 460:3 (2015), 566–571.
38. [38] Gibbs, J.E., Blaikley, J., Beesley, S., Matthews, L., Simpson, K.D., Boyce, S.H., et al. The nuclear receptor REV-ERBalpha mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. Proc. Natl. Acad. Sci. U.S.A. 109 (2012), 582–587.